ProPhase BioPharma, Inc. (PBIO), a wholly owned subsidiary of ProPhase, was formed for the licensing and development of novel drugs, compounds and biotechnology. ProPhase obtained exclusive rights worldwide to develop and commercialize Equivir (OTC/Dietary Supplement) and Equivir G (Rx). PBIO also executed a license agreement for the Linebacker portfolio (LB-1 and LB-2), two patented small molecule PIM kinase inhibitors with significant potential across multiple therapeutic indications. LB-1 is designed as an anti-cancer agent to be used as a co-therapy that targets PIM kinase receptors, a growth factor expressed in cancer.
Company Details
- Founded
- 2022
- Industry
- Biotechnology
- Website
- https://www.prophaselabs.com/
Prophase Biopharma Questions
Prophase Biopharma's website is https://www.prophaselabs.com/
Prophase Biopharma's LinkedIn profile is https://www.linkedin.com/company/prophase-biopharma
Prophase Biopharma's industry is
Biotechnology
Prophase Biopharma's top competitors are
Michal Morrison, Inc.,
Nebula Genomics,
Neurox1 Inc.,
Austin Retina Associates,
Persimmon Ridge Ventures, Llc,
Prophase Labs,
The Biotech Box,
Emx Systems,
Hanger, Inc.,
Cellready™.
Prophase Biopharma's categories are Biotechnology
Prophase Biopharma's founding year is 2022
